Other languages Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
21.7 ^USD	+4.40%		+5.47%	-9.57%

May. 31	Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing	MT
May. 20	Exelixis Settles Cabometyx Patent Litigation with Cipla	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing	May. 31
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference	May. 28
Exelixis Settles Cabometyx Patent Litigation with Cipla	May. 20
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA	May. 20
Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM	May. 14
Transcript : Exelixis, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	May. 14
Transcript : Exelixis, Inc. Presents at The Citizens JMP Life Sciences Conference, May-14-2024 09:30 AM	May. 14
Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target	May. 14
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment	May. 10
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May	May. 07
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept	May. 01
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	Apr. 30
Transcript : Exelixis, Inc., Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion	Apr. 30
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M	Apr. 30
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29	Apr. 30
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.	Apr. 30
Exelixis: Q1 Earnings Snapshot	Apr. 30
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update	Apr. 30
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024	Apr. 30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Exelixis, Inc.

Equities

EXEL

US30161Q1040

Other languages

Filters